parallel randomized trial
NCT02647944
Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Liraglutide 3.0 mg subcutaneous once daily Liraglutide 3.0 mg | lifestyle: not reported | 19 | 19 | |
| A2 | Placebo Placebo | lifestyle: not reported | 21 | 21 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Liraglutide 3.0 mg subcutaneous once daily A1 | Placebo A2 |
|---|---|---|---|
| age | mean (years) | 40.95 | 37.81 |
| age | sd (years) | 11.08 | 12.14 |
| asian | n | 1 | 0 |
| bmi | mean (kg/m2) | 37.2 | 34.6 |
| bmi | q1 (kg/m2) | 33.6 | 33.4 |
| bmi | q3 (kg/m2) | 41.0 | 38.9 |
| female | n | 17 | 18 |
| hispanic | n | 0 | 2 |
| weight | mean (kg) | 103.7 | 99.1 |
| weight | q1 (kg) | 90.0 | 90.1 |
| weight | q3 (kg) | 112.2 | 111.2 |
| white | n | 17 | 19 |
Analyses this trial contributes to
- Serious adverse eventsOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- NauseaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- NauseaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- ConstipationOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- ConstipationOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
Results
12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
All cause mortality (2 lines; O20)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 19 | not stated; randomized; registry:adverse_events | ||||
| A2 | events | 0 / 21 | not stated; randomized; registry:adverse_events |
Serious adverse events (2 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 19 | not stated; randomized; registry:adverse_events | ||||
| A2 | events | 0 / 21 | not stated; randomized; registry:adverse_events |
Discontinuation due to adverse events (2 lines; O26)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 2 / 19 | not stated; randomized; registry:flow | ||||
| A2 | events | 0 / 21 | not stated; randomized; registry:flow |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 12 / 19 | not stated; randomized; registry:adverse_events | ||||
| A2 | events | 2 / 21 | not stated; randomized; registry:adverse_events |
Diarrhea (2 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 1 / 19 | not stated; randomized; registry:adverse_events | ||||
| A2 | events | 3 / 21 | not stated; randomized; registry:adverse_events |
Constipation (2 lines; O27D)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 2 / 19 | not stated; randomized; registry:adverse_events | ||||
| A2 | events | 2 / 21 | not stated; randomized; registry:adverse_events |